February 24, 2018 |
New Treatment Options for Advanced-Stage Cancer Patients Revealed Through Next-Generation Sequencing Test
November 19, 2015  | 

New York, NY -- A powerful new test that can reveal untapped therapies for patients with advanced cancers by scanning thousands of their genes will soon be available for patients at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. The test, EXaCT-1, identifies alterations within tumors -- some of which drive cancerous growth -- on a magnitude up to hundreds of times greater than similar technologies designed to pinpoint the most precise ways of treating the disease.

Weill Cornell Medicine recently received approval for EXaCT-1 by the New York State Department of Health. The test was developed by the institutions' precision medicine team. In May, the team published findings on its first 97 patients who underwent the test and found that scanning a patient's tumor to look for any genomic mutations -- rather than limiting the screen to mutations commonly associated with a given patient's tumor type -- worked. In 92 percent of cases in the pilot program, the precision medicine team was able to recommend new treatment options based on the test's findings. Now that the state has approved the test, precision medicine leaders will begin the process to implement it for large-scale clinical use for oncology patients treated at NewYork-Presbyterian/Weill Cornell. Until that time, patients with advanced cancers will be able to access EXaCT-1 through the Caryl and Israel Englander Institute for Precision Medicine at Weill Cornell Medicine, the research enterprise of the two institutions' joint precision medicine efforts.

Page | 1 2 3 4
Suggested Articles